Citations

Showing 10 of 108135 citations.

Tao brush endometrial cytology is a sensitive diagnostic tool for cancer and hyperplasia among women presenting to clinic with abnormal uterine bleeding
DeJong, Stephanie R. , Bakkum‐Gamez, Jamie N. , Clayton, Amy C., Henry, Michael , Keeney, Gary L., Kroneman, Trynda, Laughlin‐Tommaso, Shannon K. , Ahlberg, Lisa J., VanOosten, A.L., Weaver, Amy L. , Wentzensen, Nicolas , Kerr, Sarah E. , Henry, Michael R, Kroneman, Trynda N, Laughlin-Tommaso, Shannon , VanOosten, Ann L, Wentzensen, Nicolas , Kerr, Sarah E , Zhang, Jun

Mayo Clinic

Cancer Medicine | September 17, 2021 | Volume: 10 | Issue: 20 | Pages: 7040-7047

10.1002/cam4.4235 | PMID 34532991 Get It

Abstract Background Abnormal uterine bleeding requires the investigation of the endometrium. Histology is typically used but there remains room for the improvement and use of cytology. Methods Women presenting for clinically indicated office endometrial biopsy were prospectively enrolled. Tao endometrial brushing and office endometrial biopsy were performed, and surgical procedure if clinically indicated. Tao brush cytology specimens were blindly reviewed by up to three pathologists, consensus obtained, and scored as: benign, atypical (favor benign), suspicious, positive for malignancy, or non‐diagnostic. Cytology and histology were compared to surgical pathology to determine sensitivity, specificity, positive, and negative predictive values to detect AH (atypical hyperplasia) or EC (endometrial cancer). Results Clinical indications of 197 enrolled patients included postmenopausal bleeding (90, 45.7%), abnormal uterine bleeding (94, 47.7%), and abnormal endometrium on ultrasound without bleeding (13, 6.6%). Of the 197 patients, 185 (93.9%) had cytology score consensus and a total of 196 (99.5%) had consensus regarding cytology positivity. Surgical pathology diagnoses (N = 85) were 13 (15.3%) FIGO grade 1 or 2 EC, 3 (3.5%) AH, and 69 (81.2%) benign endometrium. Sensitivity and specificity to detect EC or AH were 93.7% and 100%, respectively, via endometrial biopsy; 87.5% and 63.8%, respectively, via endometrial cytology when scores of malignancy, suspicious, or atypical were considered positive. Conclusions In a high‐risk population, Tao brush endometrial cytology showed high sensitivity to detect AH and EC comparable to biopsy histology when considering scores of malignancy, suspicious, atypical, and non‐diagnostic. Revisiting the potential value of endometrial cytology in the contemporary era of endometrial diagnostic workup is warranted.
Multi-layer endoscopic suturing: a novel method of gastric fistula closure
Zhang, Linda, Huang, Yuting , Kumbhari, Vivek , Huang, Yuting , Jovani, Manol , Zhang, Linda P.

Mayo Clinic

Endoscopy International Open | September 16, 2021 | Volume: 09 | Issue: 10 | Pages: E1520-E1523

10.1055/a-1517-4405 | PMID 34540544 Get It

Abstract Background and study aims Current endoscopic methods of treating gastric fistulas are either too complex or have high rates of recurrence. We aimed to provide a novel endoscopic method for robust fistula closure. Patients and methods This was a single-center, retrospective study of five patients who underwent multi-layer endoscopic suturing for closing of a chronic fistula (> 4 weeks). Devitalization of the fistula tract was achieved with argon plasma coagulation, followed by endoscopic suturing of the fistula. Then, endoscopic suturing of the gastric wall surrounding the fistula was performed, creating an overlay of healthy gastric mucosa around the fistula. Results Technical success (fistula closure on the day of the procedure) was achieved in all five patients, with no complications. After a median follow up of 5 months (range 2–23 months), there was a 100 % clinical success rate (no fistula recurrence). Conclusions Our single-operator method of multi-layer endoscopic suturing provides a robust fistula closure with minimal to no risk of recurrence. In light of limitations of current fistula closure methods, further investigations are warranted to better define long-term outcomes with it compared to alternative methods.
Quinacrine Induces Nucleolar Stress in Treatment-Refractory Ovarian Cancer Cell Lines
Oien, Derek B. , Ray, Upasana , Pathoulas, Christopher L., Jin, Ling , Jung, Deok‐Beom , Kumka, Joseph, Xiao, Yinan , Bhattacharya, Sayantani Sarkar , Montoya, Dennis , Chien, Jeremy , Shridhar, Viji , Jung, Deokbeom, Kumka, Joseph E, Sarkar Bhattacharya, Sayantani , Chien, Jeremey , Jin, Ling, Thirusangu, Prabhu

Mayo Clinic

Cancers | September 16, 2021 | Volume: 13 | Issue: 18 | Pages: 4645

10.3390/cancers13184645 | PMID 34572872 Get It

A considerable subset of gynecologic cancer patients experience disease recurrence or acquired resistance, which contributes to high mortality rates in ovarian cancer (OC). Our prior studies showed that quinacrine (QC), an antimalarial drug, enhanced chemotherapy sensitivity in treatment-refractory OC cells, including artificially generated chemoresistant and high-grade serous OC cells. In this study, we investigated QC-induced transcriptomic changes to uncover its cytotoxic mechanisms of action. Isogenic pairs of OC cells generated to be chemoresistant and their chemosensitive counterparts were treated with QC followed by RNA-seq analysis. Validation of selected expression results and database comparison analyses indicated the ribosomal biogenesis (RBG) pathway is inhibited by QC. RBG is commonly upregulated in cancer cells and is emerging as a drug target. We found that QC attenuates the in vitro and in vivo expression of nucleostemin (NS/GNL3), a nucleolar RBG and DNA repair protein, and the RPA194 catalytic subunit of Pol I that results in RBG inhibition and nucleolar stress. QC promotes the redistribution of fibrillarin in the form of extranuclear foci and nucleolar caps, an indicator of nucleolar stress conditions. In addition, we found that QC-induced downregulation of NS disrupted homologous recombination repair both by reducing NS protein levels and PARylation resulting in reduced RAD51 recruitment to DNA damage. Our data suggest that QC inhibits RBG and this inhibition promotes DNA damage by directly downregulating the NS–RAD51 interaction. Additionally, QC showed strong synergy with PARP inhibitors in OC cells. Overall, we found that QC downregulates the RBG pathway, induces nucleolar stress, supports the increase of DNA damage, and sensitizes cells to PARP inhibition, which supports new therapeutic stratagems for treatment-refractory OC. Our work offers support for targeting RBG in OC and determines NS to be a novel target for QC.
On-site Availability Improves Vaccination Rates in Patients With Inflammatory Bowel Disease
Farraye, Francis A. , Farraye, Francis A , Hashash, Jana G.

Mayo Clinic

Crohn's & Colitis 360 | September 16, 2021 | Volume: 3 | Issue: 4 | Pages: No page available

10.1093/crocol/otab068 | PMID 36777281 Get It

Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Fluconazole-Based Compounds with Promising Antifungal Activities
Shafiei, Mohammad , Toreyhi, Hossein , Firoozpour, Loghman , Akbarzadeh, Tahmineh , Amini, Mohsen, Hosseinzadeh, Elaheh , Hashemzadeh, Mehrnoosh , Peyton, Lee , Foroumadi, Alireza , Foroumadi, Alireza , Hashemzadeh, Mehrnoosh , Shafiei, Mohammad, Amini, Mohsen, Lotfali, Ensieh

Mayo Clinic

ACS Omega | September 16, 2021 | Volume: 6 | Issue: 38 | Pages: 24981-25001

10.1021/acsomega.1c04016 | PMID 34604679 Get It

Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene
Hsu, Fang‐Chi , Childs, Erica J., Porter, Nancy , Rabe, Kari G. , Borgida, Ayelet , Hruban, Ralph H. , Zogopoulos, George , Gallinger, Steven , Petersen, Gloria M. , Chaffee, Kari G. , Roberts, Nicholas J. , Ukaegbu, Chinedu I. , Goggins, Michael , Syngal, Sapna , Klein, Alison P.

Mayo Clinic

JAMA Oncology | September 16, 2021 | Volume: 7 | Issue: 11 | Pages: 1664

10.1001/jamaoncol.2021.3701 | PMID 34529012 Get It

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
Symmans, W. Fraser , Chen, Yunn-Yi, Klein, Molly, Nanda, Rita , Parker, Barbara A. , Datnow, Brian, Krings, Gregor , Wei, Shi , Duan, Xiuzhen, Chen, Beiyun, Sattar, Husain, Khazai, Laila , Zeck, Jay , Sams, Sharon B. , Mhawech‐Fauceglia, Paulette , Rendi, Mara H. , Sahoo, Sunati , Ocal, Idris Tolgay, Fan, Fang, LeBeau, Lauren, Vinh, Tuyethoa N., Troxell, Megan L. , Chien, A. Jo , Forero‐Torres, Andres , Ellis, Erin D. , Albain, Kathy S. , Liu, Minetta C. , Haley, Barbara , Clark, Amy S. , Kemmer, Kathleen, Lang, Julie E. , Edmiston, Kirsten K., Viscusi, Rebecca K., Northfelt, Donald W. , Khan, Qamar J. , Leyland‐Jones, Brian , Venters, Sara J., Shad, Sonal , Matthews, Jeffrey B. , Asare, Smita , Buxton, Meredith , Asare, Adam L. , Schwab, Richard B. , Veer, Laura van ‘t , Perlmutter, Jane , Yee, Douglas , Berry, Donald A. , Esserman, Laura J. , Symmans, W Fraser , Esserman, Laura J , Asare, Adam L , Yee, Douglas , Yau, Christina , Chen, Yunn‐Yi , Balassanian, Ronald , Pusztai, Lajos , Feldman, Michael D. , Wallace, Anne M. , Murthy, Rashmi Krishna , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Han, Hyo S , Matthews, Jeffrey B., Rugo, Hope S. , Helsten, Teresa L. , Hylton, Nola M. , Veer, Laura J. van’t , DeMichele, Angela

Mayo Clinic

JAMA Oncology | September 16, 2021 | Volume: 7 | Issue: 11 | Pages: 1654

10.1001/jamaoncol.2021.3690 | PMID 34529000 Get It

Dorsal Root Ganglion Stimulation for Chronic Pain After Total Knee Arthroplasty: A Narrative Review
Rupp, Adam , Char, Steven , Hagedorn, Jonathan M. , Hagedorn, Jonathan M

Mayo Clinic

Pain Medicine | September 16, 2021 | Volume: 23 | Issue: 2 | Pages: 421-423

10.1093/pm/pnab279 | PMID 34613398 Get It

Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project
Kim, Helen , Flemming, Kelly D., Nelson, Jeffrey A., Lui, Avery , Majersik, Jennifer J., Cruz, Michael Dela, Zabramski, Joseph, Trevizo, Odilette, Lanzino, Giuseppe, Zafar, Atif , Torbey, Michel , Robinson, Myranda , Narvid, Jared, Lupo, Janine, Thompson, Richard E., Hanley, Daniel F., McBee, Nichol, Treine, Kevin, Ostapkovich, Noeleen, Stadnik, Agnieszka, Piedad, Kristina, Hobson, Nicholas, Shkoukani, Abdallah , Carrión‐Penagos, Julián , Mendoza‐Puccini, Carolina , Awad, Issam A. , Flemming, Kelly D. , Mabray, Marc C , Robinson, Myranda , Carroll, Timothy , Shkoukani, Abdallah , Carrión-Penagos, Julián , Mendoza-Puccini, Carolina , Koenig, James I , Awad, Issam , Flemming, Kelly D , Kim, Helen , Nelson, Jeffrey A., Lui, Avery , Majersik, Jennifer J., Cruz, Michael Dela, Zabramski, Joseph, Trevizo, Odilette, Lanzino, Giuseppe, Zafar, Atif , Torbey, Michel , Narvid, Jared, Lupo, Janine, Thompson, Richard E., Hanley, Daniel F., McBee, Nichol, Treine, Kevin, Ostapkovich, Noeleen, Stadnik, Agnieszka, Piedad, Kristina, Hobson, Nicholas

Mayo Clinic

Stroke | September 16, 2021 | Volume: 52 | Issue: 12 | Pages: 3829-3838

10.1161/strokeaha.120.033487 | PMID 34525838 Get It

Background and Purpose: Brain cavernous angiomas with symptomatic hemorrhage (CASH) have a high risk of neurological disability from recurrent bleeding. Systematic assessment of baseline features and multisite validation of novel magnetic resonance imaging biomarkers are needed to optimize clinical trial design aimed at novel pharmacotherapies in CASH. Methods: This prospective, multicenter, observational cohort study included adults with unresected, adjudicated brain CASH within the prior year. Six US sites screened and enrolled patients starting August 2018. Baseline demographics, clinical and imaging features, functional status (modified Rankin Scale and National Institutes of Health Stroke Scale), and patient quality of life outcomes (Patient-Reported Outcomes Measurement Information System-29 and EuroQol-5D) were summarized using descriptive statistics. Patient-Reported Outcomes Measurement Information System-29 scores were standardized against a reference population (mean 50, SD 10), and one-sample t test was performed for each domain. A subgroup underwent harmonized magnetic resonance imaging assessment of lesional iron content with quantitative susceptibility mapping and vascular permeability with dynamic contrast-enhanced quantitative perfusion. Results: As of May 2020, 849 patients were screened and 110 CASH cases enrolled (13% prevalence of trial eligible cases). The average age at consent was 46±16 years, 53% were female, 41% were familial, and 43% were brainstem lesions. At enrollment, ≥90% of the cohort had independent functional outcome (modified Rankin Scale score ≤2 and National Institutes of Health Stroke Scale score <5). However, perceived health problems affecting quality of life were reported in >30% of patients (EuroQol-5D). Patients had significantly worse Patient-Reported Outcomes Measurement Information System-29 scores for anxiety ( P =0.007), but better depression ( P =0.002) and social satisfaction scores ( P =0.012) compared with the general reference population. Mean baseline quantitative susceptibility mapping and permeability of CASH lesion were 0.45±0.17 ppm and 0.39±0.31 mL/100 g per minute, respectively, which were similar to historical CASH cases and consistent across sites. Conclusions: These baseline features will aid investigators in patient stratification and determining the most appropriate outcome measures for clinical trials of emerging pharmacotherapies in CASH.